| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04231279 Details | 2024-04-03 Interventional | 3 | 27 | Secretin Abdominal Pain Exocrine Pancre… Irritable Bowel… | Data collection discontinuity and sponsor reallocation of study resources to manufacturing - | |||
| NCT04060862 2019-001072-11 Details | 2024-04-03 Interventional | 3 | 20 | Fulvestrant Ipatasertib Palbociclib Breast Neoplasm… Breast Cancer | The decision to not open the Phase III portion was based on a strategic sponsor decision and
not driven by any safety concerns. - | |||
| NCT03866980 Details | 2024-04-03 Interventional | 3 | 164 | Carboplatin Pemetrexed Carcinoma, Non-… Lung Neoplasms Lung Cancer Non… | corporate strategy adjustment - | |||
| NCT02540330 Details | 2024-04-03 Interventional | 2 | 3 | Fulvestrant Breast Neoplasm… Carcinoma Carcinoma in Si… Carcinoma, Duct… Carcinoma, Intr… Female Breast C… Female Ductal C… | Business decision (See Detailed Description) - | |||
| NCT02373241 Details | 2024-04-03 Interventional | 2 | 1 | Losartan Anemia, Sickle … Hypertension Kidney Diseases Proteinuria Kidney Disease Sickle Cell Dis… | Estimated GFR was determined not to be a reliable endpoint for this study. We identified
significant variabilty in annual eGFR that it became inappropriate to randomize to a medication
but use EGFR as the primary endpoint. - | |||
| NCT06205290 Details | 2024-04-02 Interventional | 3 | 0 | Bendamustine Hy… Cyclophosphamid… Fludarabine Idelalisib Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma | Business objectives have changed. - | |||
| NCT05400122 Details | 2024-04-02 Interventional | 1 | - | Cyclophosphamid… Fludarabine Fludarabine pho… Vactosertib Colorectal Neop… Hematologic Neo… Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Multiple Myelom… Myelodysplastic… Neoplasms Precursor Cell … Rectal Neoplasm… Syndrome Acute Lymphobla… Acute Myeloid L… Chronic Lymphoc… Chronic Myeloid… Colorectal Canc… Hematologic Mal… Hodgkin Lymphom… Myeloproliferat… Non Hodgkin Lym… Plasma Cell Mye… Rectum Cancer | Insufficient staff - | |||
| NCT05362474 Details | 2024-04-02 Interventional | 3 | 5 | Montelukast Diabetic Nephro… Kidney Diseases Diabetic Kidney… | Funding not available - | |||
| NCT05013437 Details | 2024-04-02 Interventional | 1 | 0 | Acetaminophen Diphenhydramine Melphalan Prochlorperazin… Promethazine Multiple Myelom… Neoplasms, Plas… | The original principal Investigator left the institution. - | |||
| NCT04610658 Details | 2024-04-02 Interventional | 1 | 9 | Ipilimumab Nivolumab Lung Neoplasms Recurrence Small Cell Lung… Recurrent Small… Relapsed Small … Small-cell Lung… | DLTs - | |||
| NCT03127124 Details | 2024-04-02 Interventional | 1/2 | 0 | Bevacizumab Calcium Fluorouracil Leucovorin Levoleucovorin Oxaliplatin Adenocarcinoma Pancreatic Aden… | This study was withdrawn due to no enrollment - | |||
| NCT06137651 Details | 2024-04-01 Interventional | 1 | 0 | Vinorelbine Breast Neoplasm… Neoplasms Neoplasms, Seco… Breast Carcinom… Metastatic Mali… Metastatic Mali… | Study terminated by the sponsor - | |||
| NCT05617625 Details | 2024-04-01 Interventional | 2 | - | Busulfan Fludarabine Melphalan Graft vs Host D… Myelodysplastic… Preleukemia Syndrome Graft Vs Host D… Graft-versus-ho… | The study has been put on hold while pending CMS approval - | |||
| NCT04945733 Details | 2024-04-01 Interventional | 2 | 62 | Amivantamab-vmj… Esophageal Neop… Neoplasms Stomach Neoplas… | Due to reconsideration of development strategy - | |||
| NCT06083883 Details | 2024-03-29 Interventional | 1 | - | Cyclophosphamid… Fludarabine Fludarabine pho… Liposarcoma Liposarcoma, My… Sarcoma Sarcoma, Synovi… Myxoid/Round Ce… Synovial Sarcom… | Activate and Hold per IND office - | |||
| NCT05815186 Details | 2024-03-29 Interventional | 2 | 0 | Sotorasib Carcinoma, Non-… Lung Neoplasms Advanced Non-sm… | Study record has been combined with NCT05815173 (Phase I/II study). - | |||
| NCT05289492 Details | 2024-03-29 Interventional | 1/2 | 16 | Dexamethasone Multiple Myelom… Neoplasms, Plas… | Company operational decision. Decision to stop study is not due to safety or efficacy concerns - | |||
| NCT04300114 Details | 2024-03-28 Interventional | 3 | 5 | Fluzoparib Pancreatic Neop… Metastatic Panc… | Sponsor R & D Strategy Adjustment - | |||
| NCT03983824 Details | 2024-03-28 Interventional | 1 | - | Cytarabine Etoposide Etoposide phosp… Mitoxantrone Peposertib Leukemia Leukemia, Myelo… Leukemia, Myelo… Recurrent Acute… Refractory Acut… | Scheduled Interim Monitoring - | |||
| NCT03743025 Details | 2024-03-28 Interventional | 4 | 31 | Dulaglutide Hyperglycemia Stress Hypergly… | The study was terminated following the Data and Safety Monitoring Board (DSMB) review due to
concerns with perioperative use of the study drug. - |